Company Profile · Healthcare

Imeik Technology Development Co

300896 · Shenzhen
Industry
Medical Devices
Exchange
Shenzhen
Country
China
Employees
1,458
Website
www.imeik.net/cn
Current Price
¥95
Live · Oct 5, 2026
Fair Buy
≤ ¥64
Margin-of-safety entry
Baillie Growth Score
43/100
Weak
Buffett Score
78/100
Strong
Intrinsic Value · Three-Tier Range Current price ¥95 Live · Within the fair intrinsic-value range

Composite valuation range · conservative ¥56–¥64 / fair ¥90–¥120 / optimistic ¥160–¥175. At ¥95, Within the fair intrinsic-value range.

At publication ¥92.68 (Sep 21, 2026)

Financial snapshot
Market capCN¥28.75B
Revenue (TTM)CN¥2.37B
EBITDACN¥1.15B
Profit margin46.22%
ROE13.44%
P/E (TTM)26.17
Forward P/E17.76
PEG0.96
EPSCN¥3.63
Dividend yield1.96%
52-week rangeCN¥82.46 – CN¥178.80

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

About the company

Imeik Technology Development Co.,Ltd. engages in the research and development, and transformation of biomedical materials and biopharmaceutical products in China. The company offers aesthetic medicine products, such as cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere; poly facial implant thread; medical sodium hyaluronate-hydroxypropyl methylcellulose gel; sodium hyaluronate composite solution for injection; modified sodium hyaluronate gel for injection; medical PVA gel ball-sodium hyaluronate-hydroxypropyl methylcellulose gel; and skin care products. It serves medical aesthetic institutions. The company was incorporated in 2004 and is headquartered in Beijing, China.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

Research on this stock
43/100 Hold Imeik: New Powder Replaced 71% of the Revenue the Legacy Injectables Lost, But Selling Expense Rose 63% While Sales Fell 6% Imeik makes regulated Class III injectable devices for China's medical-aesthetics market, where hyaluronic-acid solution and gel fillers long produced gross margins above 90% and net margins near 60%. Those two lines fell 20.51% and 23.08% in the first half of 2026 while the new lyophilised PDLLA powder grew to CNY 209.0m and replaced about 71% of the revenue they lost, and selling expense rose 62.89% to CNY 234.8m even as sales fell 6.42%. Rating Hold: at CNY 92.68 the shares sit inside the CNY 90 to 120 acceptable-hold band rather than the CNY 56 to 64 ideal-buy zone, so the conservative CNY 70 to 80 fair value leaves no margin of safety. Imeik Technology Development Co., Ltd.300896 · ShenzhenMedical DevicesSep 21, 2026